



# High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants

Peter Willeit, MD, MPHIL, PhD,<sup>a,b</sup> Paul Welsh, PhD,<sup>c</sup> Jonathan D.W. Evans, MBChB,<sup>b,d</sup> Lena Tschiderer, DIPL-ING, BSc,<sup>a</sup> Charles Boachie, BSc,<sup>c</sup> J. Wouter Jukema, MD, PhD,<sup>e</sup> Ian Ford, PhD,<sup>f</sup> Stella Trompet, PhD,<sup>g</sup> David J. Stott, MD,<sup>c</sup> Patricia M. Kearney, MD, PhD,<sup>h</sup> Simon P. Mooijaart, MD, PhD,<sup>g</sup> Stefan Kiechl, MD,<sup>a</sup> Emanuele Di Angelantonio, MD, MSc, PhD,<sup>b,i,j,k</sup> Naveed Sattar, MD, PhD<sup>c</sup>

## ABSTRACT

**BACKGROUND** High-sensitivity assays can quantify cardiac troponins I and T (hs-cTnI, hs-cTnT) in individuals with no clinically manifest myocardial injury.

**OBJECTIVES** The goal of this study was to assess associations of cardiac troponin concentration with cardiovascular disease (CVD) outcomes in primary prevention studies.

**METHODS** A search was conducted of PubMed, Web of Science, and EMBASE for prospective studies published up to September 2016, reporting on associations of cardiac troponin concentration with first-ever CVD outcomes (i.e., coronary heart disease [CHD], stroke, or the combination of both). Study-specific estimates, adjusted for conventional risk factors, were extracted by 2 independent reviewers, supplemented with de novo data from PROSPER (Pravastatin in Elderly Individuals at Risk of Vascular Disease Study), then pooled by using random effects meta-analysis.

**RESULTS** A total of 28 relevant studies were identified involving 154,052 participants. Cardiac troponin was detectable in 80.0% (hs-cTnI: 82.6%; hs-cTnT: 69.7%). In PROSPER, positive associations of log-linear shape were observed between hs-cTnT and CVD outcomes. In the meta-analysis, the relative risks comparing the top versus the bottom troponin third were 1.43 (95% confidence interval [CI]: 1.31 to 1.56) for CVD (11,763 events), 1.67 (95% CI: 1.50 to 1.86) for fatal CVD (7,775 events), 1.59 (95% CI: 1.38 to 1.83) for CHD (7,061 events), and 1.35 (95% CI: 1.23 to 1.48) for stroke (2,526 events). For fatal CVD, associations were stronger in North American studies ( $p = 0.010$ ) and those measuring hs-cTnT rather than hs-cTnI ( $p = 0.027$ ).

**CONCLUSIONS** In the general population, high cardiac troponin concentration within the normal range is associated with increased CVD risk. This association is independent of conventional risk factors, strongest for fatal CVD, and applies to both CHD and stroke. (J Am Coll Cardiol 2017;70:558-68) © 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).



Listen to this manuscript's  
audio summary by  
JACC Editor-in-Chief  
Dr. Valentin Fuster.



From the <sup>a</sup>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria; <sup>b</sup>Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; <sup>c</sup>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom; <sup>d</sup>Transplant Unit, Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, United Kingdom; <sup>e</sup>Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands; <sup>f</sup>Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom; <sup>g</sup>Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands; <sup>h</sup>Department of Epidemiology and Public Health, University College Cork, Cork, Ireland; <sup>i</sup>National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom; <sup>j</sup>NHS Blood and Transplant, Cambridge, United Kingdom; and the <sup>k</sup>British Heart Foundation Cambridge Centre of Excellence, University of Cambridge, Cambridge, United Kingdom. Dr. Willeit was supported by an Erwin Schrödinger-Fellowship sponsored by the Austrian Science Fund (J-3679-B13). Dr. Willeit, Mrs. Tschiderer, and Dr. Kiechl were supported by the excellence initiative (Competence Centers for Excellent Technologies) of the Austrian Research Promotion

Cardiac troponins are structural proteins in the contractile apparatus of cardiac myocytes that are released into the circulation after cardiac myocyte cell death (1). Since the introduction of the first troponin assays in the early 1990s, measurement of circulating cardiac troponin concentration has become a cornerstone in the diagnosis and acute management of myocardial infarction (MI) (2). Development of high-sensitivity assays allowed the detection of cardiac troponin I and T (hs-cTnI and hs-cTnT, respectively) at lower concentrations, which enabled earlier identification of myocardial injury and increased diagnostic accuracy in patients with suspected MI (3).

At the same time, these methodological advances have led to a fundamental change in the clinical interpretation of cardiac troponin assay results. Although patients traditionally have been classified as being “troponin-positive” or “troponin-negative” in the context of the diagnosis of acute MI, new-generation assays allow a continuous interpretation of findings (i.e., higher vs. lower concentration). Furthermore, high-sensitivity assays can detect circulating cardiac troponin in individuals with no clinically manifest myocardial damage or previous cardiovascular disease (CVD).

SEE PAGE 569

Recent studies in subjects recruited from the general population have suggested that elevations in circulating cardiac troponin are associated with a higher risk of a first-ever CVD event (4–30). The largest such study, from the BiomarcARE (Biomarkers for Cardiovascular Risk Assessment in Europe) consortium, reported a hazard ratio (HR) for CVD of 1.92 (95% confidence interval [CI]: 1.76 to 2.10) comparing the highest versus the lowest quintile of hs-cTnI concentration (11). Although these studies have yielded promising findings, their interpretation and comparison have been hampered by use of different scales and inconsistent adjustment of effect estimates. To clarify associations of cardiac troponins with incident CVD, the present study collated effect estimates from published studies conducted in populations free of previous CVD, supplemented

them with de novo data, and combined them in a meta-analysis.

## METHODS


We systematically searched the electronic databases PubMed, Web of Science, and EMBASE for prospective studies published up to September 2016 that reported on associations of cardiac troponin concentration with incident CVD outcomes. The search strategy is detailed in [Online Table 1](#). Studies were eligible for inclusion if they: 1) had measured hs-cTnI and/or hs-cTnT with a high-sensitivity assay; 2) had recruited participants not based on having a history of CVD at baseline; and 3) had recorded CVD outcomes over more than 1 year of follow-up. We further obtained unpublished tabular data from the Bruneck Study through direct correspondence with study investigators (31). Using standardized data extraction protocols, 2 independent reviewers (P.W. and J.D.W.E.) extracted, by consensus, information on geographical location, baseline survey dates, study design, exclusion of participants with pre-existing CVD, mean age at baseline, proportion of male subjects, proportion of white participants, sample type, cardiac troponin assay manufacturer, assay detection limit, proportion of participants with detectable cardiac troponin, and number of participants in the study. In relation to incident outcomes, the reviewers extracted data on duration of follow-up, the specific composition of reported endpoints, the number of outcomes accrued, effect sizes, and the degree of statistical adjustment of any reported association. The degree of adjustment was classified as “o” when relative risks (RRs) were adjusted for age and sex only, “+” when RRs were adjusted for conventional risk factors (age, sex, smoking, diabetes, blood pressure, and total and high-density lipoprotein cholesterol [HDL-C]); “++” when RRs were also adjusted for C-reactive protein (CRP) or serum creatinine; and “+++” after further adjustment for B-type natriuretic peptides. If multiple publications on the same study were available,

## ABBREVIATIONS AND ACRONYMS

**CHD** = coronary heart disease  
**CI** = confidence interval  
**CRP** = C-reactive protein  
**CVD** = cardiovascular disease  
**eGFR** = estimated glomerular filtration rate  
**HDL-C** = high-density lipoprotein cholesterol  
**HR** = hazard ratio  
**hs-cTnI** = high-sensitivity cardiac troponin I  
**hs-cTnT** = high-sensitivity cardiac troponin T  
**MI** = myocardial infarction  
**NRI** = net reclassification index  
**NT-proBNP** = N-terminal pro-B-type natriuretic peptide  
**RR** = relative risk

Agency FFG: “Research Center of Excellence in Vascular Ageing–Tyrol, VASCage” (K-Project No. 843536) funded by the BMVIT, BMWFW, Wirtschaftsagentur Wien, and Standortagentur Tirol. Dr. Evans was supported by the BHF Cambridge Centre for Research Excellence. Drs. Welsh and Sattar’s cardiac biomarker work is supported by a stratified medicine grant from the Chief Scientist Office of the Scottish Government (ASM/14/1). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Willeit, Welsh, and Evans contributed equally to this work as joint first authors. Drs. Di Angelantonio and Sattar contributed equally to this work as joint senior authors.

Manuscript received April 6, 2017; revised manuscript received May 30, 2017, accepted May 30, 2017.



the most up-to-date or comprehensive information was used. Methods and results are reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines (32).

**THE PROSPER STUDY.** PROSPER (Pravastatin in Elderly Individuals at Risk of Vascular Disease Study) was a randomized, double-blind, placebo-controlled pravastatin trial in individuals with pre-existing CVD or risk factors thereof (i.e., smoking, hypertension, diabetes) (33,34). The present analysis involved 4,402 participants with no previous CVD and with complete information on hs-cTnT and covariates, recruited at study centers in Scotland, Ireland, and the Netherlands (Online Figure 1). Measurement of hs-cTnT used plasma samples obtained 6 months after randomization using a

high-sensitivity electrochemiluminescence immunoassay. The occurrence of incident outcomes was adjudicated by the PROSPER Endpoints Committee during the in-trial phase (mean duration: 3.2 years) and ascertained with routine health data thereafter. The institutional ethics review boards of all centers approved the protocol, and all participants gave written informed consent. The protocol adhered to the principles of the Declaration of Helsinki. Further details are provided in the Online Appendix.

**STATISTICAL ANALYSIS.** The statistical analysis was conducted according to a pre-defined statistical analysis plan. The combined CVD endpoint was defined as fatal coronary heart disease (CHD), nonfatal MI, and fatal plus nonfatal stroke (ischemic, hemorrhagic, or unclassified). In PROSPER, we assessed cross-sectional associations between hs-cTnT and other characteristics by using linear and logistic regression models (for continuous and categorical data, respectively), adjusted for age, sex, center, and treatment arm. HRs were calculated for CVD outcomes stratified according to treatment arm and were progressively adjusted for age, sex, and center (model 1), plus smoking, history of diabetes mellitus, history of hypertension, systolic blood pressure, total cholesterol, HDL-C, and body mass index (model 2), plus CRP, estimated glomerular filtration rate (eGFR), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (model 3).

To characterize shapes of associations with CVD outcomes, HRs were calculated across quartiles of detectable hs-cTnT concentration by using participants with undetectable hs-cTnT as the reference group, and HRs were plotted against the median hs-cTnT concentration within each category. For the outcomes of CVD and fatal CVD, effect modification was explored across clinically relevant subgroups with formal tests of interaction. We also tested whether assessment of hs-cTnT, in addition to age, sex, smoking status, history of diabetes mellitus, systolic blood pressure, and levels of total cholesterol and HDL-C, could improve the prediction of 10-year CVD risk. C-index changes as well as categorical and continuous net reclassification indexes (NRIs) were calculated by using previously published methods (35,36). Categorical NRIs were calculated across 10-year predicted risk categories of <15%, 15% to <25%, and ≥25%, chosen to reflect the elevated risk in the study population; 95% CIs were estimated for these prediction metrics by using bootstrap resampling with 999 repetitions.

Study-specific risk estimates were pooled by using random effects meta-analyses. Odds ratios and HRs were assumed to approximate the same underlying

measure of RR. When studies reported RRs of various levels of adjustment, the most adjusted estimate was used. To enable a consistent approach to analysis, RRs and 95% CIs in each study were standardized to a common scale (i.e., to reflect a comparison of the top third vs. the bottom third of the population's cardiac troponin distribution, using methods previously described) (37). Consistency of findings across studies was assessed with standard chi-square tests and the  $I^2$  statistic (38). Subgroup analyses were conducted by using meta-regression across pre-specified study-level characteristics (39). Evidence of publication bias was assessed by using funnel plots and Egger's asymmetry test (40). Statistical tests were 2-sided and used a significance level of  $p < 0.05$  for principal analyses and  $p < 0.01$  for subgroup analyses.

## RESULTS

In PROSPER, hs-cTnT was detectable in 3,853 (87.5%) of 4,402 participants. The median concentration of hs-cTnT was 7 ng/l (interquartile range: 4 to 11 ng/l), and 85% of hs-cTnT values were within the normal range of  $\leq 14$  ng/l. Concentration of hs-cTnT correlated positively with age, male sex, body mass index, blood pressure, NT-proBNP, CRP, history of diabetes mellitus, and history of hypertension (Online Table 2). Concentration of hs-cTnT was lower in current smokers and correlated inversely with renal function assessed by eGFR. There was no difference in hs-cTnT according to trial arm.

In the overall cohort, 694 fatal CVD events were recorded over a follow-up duration of up to 11.3 years (mean: 8.2 years). At the Scottish center, 519 fatal and nonfatal CVD events, 405 CHD events, and 269 stroke events were recorded. After adjusting for age, sex, smoking, history of diabetes mellitus, history of hypertension, systolic blood pressure, total cholesterol, HDL-C, and body mass index, the shapes of associations between baseline hs-cTnT concentration and CVD outcomes were approximately log linear (Figure 1). The adjusted HRs for a comparison of the top third versus the bottom third of the hs-cTnT concentration were 1.55 (95% CI: 1.23 to 1.96) for CVD, 2.16 (95% CI: 1.74 to 2.67) for fatal CVD, 1.85 (95% CI: 1.42 to 2.42) for CHD, and 1.21 (95% CI: 0.88 to 1.67) for stroke. There was some attenuation of estimates after further adjustment for CRP, eGFR, and NT-proBNP (Online Table 3). There was no evidence for effect modification by a range of participant characteristics, including age, sex, diabetes, eGFR, and NT-proBNP, but there was evidence for a somewhat stronger association in never- or ex-smokers compared with current smokers (Online Figure 2).

**LITERATURE-BASED META-ANALYSIS.** We screened 4,645 records and identified 28 eligible prospective studies (4–30) reporting on a total of 154,052 participants (Table 1, Online Figure 3). Eighteen studies were based in Europe, 7 in North America, 1 in Asia, and 2 were multinational. The mean age was 56.1 years, 52.8% of participants were male, and 88.6% were white. Seventeen studies had measured hs-cTnI and 11 had measured hs-cTnT. The proportion of participants with detectable cardiac troponin concentrations was 80.0% overall (82.6% in hs-cTnI studies and 69.7% in hs-cTnT studies). Multivariable regression analyses weighting studies according to their size identified that the proportion of participants with detectable troponin was higher in hs-cTnI studies ( $p = 0.007$ ) and in older study populations (8.3% per decade higher mean age;  $p = 0.009$ ) but was unrelated to sex distributions ( $p = 0.155$ ). Figure 2 displays the proportion of troponin detection according to study, assay type, and mean age of the study population.

The combined RR in the top third versus the bottom third of cardiac troponin concentration was 1.43 for CVD, 1.67 for fatal CVD, 1.59 for CHD, and 1.35 for stroke (Figure 3). Forest plots for each outcome are shown in Online Figures 4 to 7. The level of between-study heterogeneity was low for stroke ( $I^2 = 0\%$ ;  $p = 0.764$ ) and high for other outcomes ( $I^2 > 75\%$ ; all  $p < 0.001$ ). Magnitudes of associations with CVD and fatal CVD were largely similar across studies grouped according to geographical regions, in studies nested versus those not nested in clinical trials (Online Figure 8), and for different mean ages of study participants, proportions of male participants, and numbers of recorded events (Online Figure 9). Associations for fatal CVD were somewhat stronger in studies based in North America ( $p = 0.010$ ) (Online Figure 8) and studies measuring hs-cTnT rather than hs-cTnI ( $p = 0.027$ ) (Online Figure 8). Associations with CVD were stronger in studies with a higher proportion of nonwhite participants ( $p = 0.004$ ) (Online Figure 9). There was evidence for publication bias in reporting associations with fatal CVD ( $p_{\text{Egger}} = 0.027$ ) but not for the other outcomes assessed (Online Figure 10).

The addition of hs-cTnT concentration to a prediction model containing information on conventional risk factors improved the prediction of fatal CVD (Online Table 4). It improved the C-index by 0.028 (95% CI: 0.007 to 0.050;  $p = 0.018$ ), the categorical NRI by 0.123 (95% CI: 0.074 to 0.153;  $p < 0.001$ ), and the continuous NRI by 0.357 (95% CI: 0.277 to 0.436;  $p < 0.001$ ). In contrast, for the overall CVD outcome, smaller improvements in the continuous NRI of 0.152 (95% CI: 0.052 to 0.253;  $p = 0.003$ ) were observed, whereas no improvements were observed in the

**TABLE 1** Characteristics of Prospective Studies

Study (Ref. #)	Location	Baseline Survey Date (Range)	Study Design	Mean Follow-Up, Yrs	Mean Age, Yrs	Male, %	White, %
ADVANCE (4)	United States	2001-2004	PC	11.3*	62.1	50.8	62.1
AGES-Reykjavik (5)	Iceland	2002-2006	PC	8.2*	77.0	42.5	100.0
ARIC (6-9)	United States	1996-1998	PC	12.1	62.7	43.8	78.3
BRHS (10)	United Kingdom	1998-2000	PC	13.0*	68.6	100.0	99.0
BRIANZA (11)	Italy	1986-1993	PC	15.0*	46.7*	49.3	NR
BRUN	Italy	2000	PC	10.0†	65.4	46.1	100.0
CAERPHILLY (11)	United Kingdom	1989-1993	PC	22.2†	62.4*	100.0	100.0
CHS (12,13)	United States	1989-1993	PC	11.8*	72.7	40.5	83.8
CIRCS (14)	Japan	2001-2011	NCC	2.0*	38.0-86.0‡	68.0	0.0
DAN-MONICA (11)	Denmark	1982-1992	PC	29.0†	50.0*	50.6	NR
DHS (15)	United States	2000-2002	PC	6.4*	44.8	44.1	29.4
FHS (16)	United States	1995-1998	PC	11.3	59.0	46.9	100.0
FINRISK97 (17)	Finland	1997	PC	14.0†	47.8*	49.7	100.0
HUNT2 (18,19)	Norway	1995-1997	PC	13.9	50.0*	45.6	97.0
JUPITER (20)	Multinational	2003-2006	PC§	2.0*	66.0*	67.7	81.8
KORA (11,21)	Germany	1994-2001	PC/CCoh	14.5†	50.5*	49.7	NR
MFS (10)	United Kingdom	1996	PC	17.3*	45.1	44.5	100.0
MHS (22)	United States	1990-1997	NCC	15.0†	67.0	62.1	97.0
MOLI-SANI (11)	Italy	2005-2010	PC	4.2*	54.6*	48.1	NR
PIVUS (23,24)	Sweden	2001	PC	10.0*	70.0	50.0	100.0
PREVEND (25)	Netherlands	1997	PC	12.0†	49.3	49.8	94.9
PRIME-BEL (11)	United Kingdom	1990-1993	PC	12.0†	54.7*	100.0	NR
PROSPER	Multinational	1997-1999	PC§	8.2	75.3	44.8	100.0
SHHEC (11,29)	United Kingdom	1984-1995	PC	20.0	48.9	50.4	NR
SHIP (11)	Germany	1997-2001	PC	11.0†	50.0*	48.7	NR
ULSAM (26)	Sweden	1991-1995	PC	10.0*	71.0	100.0	100.0
WHS (27)	United States	1992-1995	PC/CCoh§¶	12.3*	56.5*	0.0	90.8
WOSCOPS (28)	United Kingdom	1989-1991	PC§	15.0†	55.1	100.0	NR
Total		1982-2011		11.9	56.1	52.8	88.6

Values are ranges, weighted means, or sums, unless otherwise indicated. \*Median. †Maximum. ‡Range. §Prospective study was nested in a trial. ||The KORA study reported on the association with CHD events in a case-cohort dataset (2,748 participants, maximum follow-up of 16 years, hs-cTnI measured with the Erenna assay). ¶The WHS investigated results separately for participants with and without diabetes (using a prospective study and case-cohort design, respectively).

ADVANCE = Atherosclerotic Disease, Vascular Function and Genetic Epidemiology Study; AGES-Reykjavik = Age, Gene/Environment Susceptibility-Reykjavik Study; ARIC = Atherosclerosis Risk in Communities Study; BRHS = British Regional Heart Study; BRIANZA = MONICA Brianza Study; BRUN = Bruneck Study; CAERPHILLY = Caerphilly Prospective Study; CCoh = case-cohort study; CHD = coronary heart disease; CHS = Cardiovascular Health Study; CIRCS = Circulatory Risk in Communities Study; CVD = cardiovascular disease; DAN-MONICA = Danish MONICA Study; DHS = Dallas Heart Study; FHS = Framingham Heart Study; FINRISK97 = FINRISK 1997 Survey; hs-cTnI = high-sensitivity cardiac troponin I; hs-cTnT = high-sensitivity cardiac troponin T; HUNT2 = Nord-Trøndelag Health Study 2; JUPITER = Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin Trial; KORA = Kooperative Gesundheitsforschung in der Region Augsburg; MFS = MIDSPAN Family Study; MHS = Minnesota Heart Study; MOLI-SANI = Moli-Sani Project; NCC = nested case-control study; NR = not reported; PC = prospective cohort study; PIVUS = Prospective Investigation of the Vasculature in Uppsala Seniors Study; PREVEND = Prevention of Renal and Vascular End Stage Disease Study; PRIME-BEL = Prospective Epidemiological Study of Myocardial Infarction from Belfast; PROSPER = Pravastatin in Elderly Individuals at Risk of Vascular Disease Study; SHHEC = Scottish Heart Health Study and Scottish MONICA; SHIP = Study of Health in Pomerania; ULSAM = Uppsala Longitudinal Study of Adult Men; WHS = Women's Health Study; WOSCOPS = West of Scotland Coronary Prevention Study.

C-index ( $p = 0.51$ ) and the categorical NRI ( $p = 0.25$ ). Detailed reclassification data are provided in [Online Table 5](#).

## DISCUSSION

In the present report that combined de novo data from the PROSPER study with a comprehensive literature-based meta-analysis, we reliably quantified associations of baseline cardiac troponin measurements with first-ever CVD outcomes ([Central Illustration](#)). We further determined the added predictive value of such measurements in the primary prevention of CVD.

**ASSOCIATIONS WITH CVD OUTCOMES.** Overall, the present systematic review and meta-analysis involved data from 28 long-term prospective studies with a total of 154,052 participants without previous CVD. All included studies measured cardiac troponins hs-cTnT or hs-cTnI with high-sensitivity assays and reported detectable levels in 80% of people, on average. Pooled estimates from the meta-analysis suggest that individuals with cardiac troponin values in the top third of the population distribution are at 43% increased risk of any CVD, 59% increased risk of CHD, and 67% increased risk of fatal CVD outcomes. A smaller but significant increase in stroke risk (35%) was noted. It is likely that

**TABLE 1** Continued


Type of Troponin (Assay)	Sample Type	Detection Limit, ng/l	Detectable Troponin, %	Participants, n	No. of Events			
					CVD	CHD	Stroke	Fatal CVD
hs-cTnI (Abbott)	Serum	1.2	100	1,135	-	164	-	-
hs-cTnI (Abbott)	Serum	1.2	100	5,691	957	716	-	-
hs-cTnT (Roche)	Plasma	3.0	68	10,350	610	527	507	358
hs-cTnT (Roche)	Plasma	3.0	99	2,715	475	-	-	-
hs-cTnI (Abbott)	Serum	1.9	75	4,932	393	-	-	167
hs-cTnT (Roche)	Serum	12.0	95	642	74	33	37	49
hs-cTnI (Abbott)	Serum	1.9	75	2,171	583	-	-	470
hs-cTnT (Roche)	Serum	3.0	66	4,221	-	-	NR	1,103
hs-cTnT (Roche)	Serum	3.0	NR	360	-	120	-	-
hs-cTnI (Abbott)	Serum	1.9	75	7,582	1,326	-	-	1,002
hs-cTnT (Roche)	Serum	3.0	27	3,459	-	-	-	59
hs-cTnI (Erenna)	Plasma	0.2	81	3,265	334	173	-	-
hs-cTnI (Erenna)	Serum	1.0	94	7,899	770	363	299	-
hs-cTnI (Abbott)	Serum	1.2	96	9,712	-	292	-	708
hs-cTnI (Abbott)	Plasma	1.9	92	12,956	304	224	70	46
hs-cTnI (Abbott)	Serum	1.9	75	8,913	525	803	-	331
hs-cTnT (Roche)	Plasma	3.0	95	1,721	135	-	-	-
hs-cTnI (Erenna)	Serum	NR	100	464	-	-	-	211
hs-cTnI (Abbott)	Serum	1.9	75	24,325	473	-	-	151
hs-cTnI (Abbott)	Plasma	1.5	96	1,004	163	-	-	37
hs-cTnT (Roche)	Plasma	3.0	NR	8,121	-	583	-	-
hs-cTnI (Abbott)	Serum	1.9	75	2,745	505	-	-	149
hs-cTnT (Roche)	Plasma	3.0	88	4,402	519	405	269	694
hs-cTnI (Abbott)	Serum	1.9	75	16,000	2,953	1,980	797	1,786
hs-cTnI (Abbott)	Serum	1.9	75	3,871	-	-	-	38
hs-cTnT (Roche)	Plasma	3.0	93	561	148	86	62	46
hs-cTnT (Roche)	Plasma	3.0	35	1,517	516	176	272	119
hs-cTnI (Abbott)	Plasma	1.2	99.8	3,318	-	413	213	251
			80.0	154,052	11,763	7,061	2,526	7,775

this association was driven by cardiac and heart rhythm abnormalities causing ischemic stroke, including paroxysmal atrial fibrillation (41). An analysis of the Atherosclerosis Risk in Communities Study according to stroke subtype revealed preferential associations of hs-cTnT with cardioembolic stroke (8). Furthermore, Wrigley et al. (42) recently reported that, in patients with acute ischemic stroke, an elevated troponin concentration was associated with structural cardiac disease detected by using echocardiography.

Our findings in the meta-analysis were further substantiated by analyses of PROSPER study data, showing that subjects with higher blood

concentrations of hs-cTnT were at higher risk of developing fatal and nonfatal CVD and CHD. Associations were independent of conventional CVD risk factors and persisted even after additional adjustment for NT-proBNP, eGFR, and CRP. We could also confirm a previous suggestion from the BiomarcARE consortium (11) that the risk of these diseases increased approximately log linearly with higher cardiac troponin concentration, with no evidence for a threshold effect at a certain level. It is striking that we observed significant positive associations with CVD outcomes even though 85% of the study population had hs-cTnT values within the normal range ( $\leq 14$  ng/l) at baseline.



**FIGURE 2** Detectable Cardiac Troponin Concentrations





The percentage of participants with detectable cardiac troponin concentrations was categorized by mean age and assay type per included study. The **red line** and **gray area** represent the line of best fit and 95% confidence interval, respectively, with individual studies being weighted according to their number of participants. ADVANCE = Atherosclerotic Disease, Vascular Function and Genetic Epidemiology Study; AGES-Reykjavik = Age, Gene/Environment Susceptibility-Reykjavik Study; ARIC = Atherosclerosis Risk in Communities Study; BiomarCaRE = Biomarkers for Cardiovascular Risk Assessment in Europe; BRHS = British Regional Heart Study; BRUN = Bruneck Study; CHS = Cardiovascular Health Study; DHS = Dallas Heart Study; FHS = Framingham Heart Study; FINRISK97 = FINRISK 1997 Survey; hs-cTnT = high-sensitivity cardiac troponin T; HUNT2 = Nord-Trøndelag Health Study 2; JUPITER = Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin Trial; MFS = MIDSPAN Family Study; MHS = Minnesota Heart Study; PIVUS = Prospective Investigation of the Vaculature in Uppsala Seniors Study; PROSPER = Pravastatin in Elderly Individuals at Risk of Vascular Disease Study; ULSAM = Uppsala Longitudinal Study of Adult Men; WHS = Women's Health Study; WOSCOPS = West of Scotland Coronary Prevention Study.

We also detected significant between-study heterogeneity for the associations with the outcomes of all CVD and fatal CVD. Studies varied in their age and sex profile, outcome definitions, follow-up durations, and degrees of statistical adjustment, but none of these factors had an influence on the strengths of associations observed. However, our analysis revealed possibly stronger associations in studies based in North America and with a higher proportion of nonwhite participants. Although it is well established that nonwhite participants have higher cardiac troponin values compared with white participants (4,7,8,12,15), single studies have so far not detected that associations of cardiac troponins with CHD (7) or stroke (8) are modified according to ethnicity. Furthermore, we noted a trend toward stronger associations for hs-cTnT than for hs-cTnI.

To shed more light on this preliminary finding, future research is needed that evaluates, in a direct comparison, whether the clinical utility of hs-cTnT and hs-cTnI measurements depends on the assay generation or on patient characteristics, including age, sex, and indicators of myocardial stress. Although findings in PROSPER and 3 previous studies (8,25,26) suggested that the prognostic value of cardiac troponins does not vary according to NT-proBNP levels, analysis of large-scale individual-participant data is required to assess multiplicative interactions adequately.

**BIOLOGICAL MECHANISMS.** The traditional view has been that cardiac troponins are elevated in case of myocardial necrosis only; however, evidence has emerged that other heart diseases such as atrial fibrillation (43) and cardiac structural and functional

**FIGURE 3 Combined Adjusted Relative Risk for CVD Outcomes**

Outcome	No. of			Relative Risk Comparing Top vs. Bottom Third of Cardiac Troponin (95% CI)	I <sup>2</sup> Value
	Studies	Participants	Events		
CVD	19	112,251	11,763	 1.43 (1.31, 1.56)	82.8%
Fatal CVD	20	122,094	7,775	 1.67 (1.50, 1.86)	84.1%
CHD	16	83,950	7,061	 1.59 (1.38, 1.83)	77.6%
Stroke	10	58,450	2,526	 1.35 (1.23, 1.48)	0.0%

Study-specific relative risks were pooled by using random effects meta-analysis and compared in the top third versus the bottom third of cardiac troponin concentration. Abbreviations as in [Figure 1](#).

abnormalities (15,44) can also lead to modest increases in cardiac troponin concentrations in circulation. Another relevant factor could be subclinical coronary atherosclerosis. Coronary angiography studies have shown close correlations between the severity of coronary atherosclerosis and cardiac troponin concentration (45). It is speculated that clinically silent ruptures of coronary plaques trigger

microembolizations and, consequently, the shedding of troponin from cardiomyocytes via membranous blebs (46). A third mechanism could be the link between cardiac troponin concentration and cardiac stress characterized by activation of the adrenergic and renin-angiotensin-aldosterone systems. This relationship has been demonstrated in patients with heart failure (47).


### CENTRAL ILLUSTRATION Troponin and Risk of CVD Outcomes

#### Study Data

154,052 participants without CVD  
recruited by 28 prospective studies

#### Cardiac Troponin Concentration

Detectable in 80% with high-sensitivity assays



#### Risk of a First-ever CVD Event

Relative risk comparing top vs. bottom third

CVD	+43%
Fatal CVD	+67%
CHD	+59%
Stroke	+35%

Willeit, P. et al. *J Am Coll Cardiol*. 2017;70(5):558-68.

In assessing the association of cardiac troponin concentration and CVD outcomes, we identified 28 relevant studies. Thirds of cardiac troponin concentration were defined within each study separately. Study-specific relative risks for first-ever CVD outcomes were pooled by using a random effects meta-analysis, demonstrating that high cardiac troponin levels in the normal range are associated with increased CVD event risk. The distribution graph is illustrative and cardiac troponin distributions were not normally distributed. CHD = coronary heart disease; CVD = cardiovascular disease.



**CLINICAL RELEVANCE.** Our data also suggested that cardiac troponin assessment could be a useful adjunct to conventional risk factors in predicting CVD risk. In line with a preferential association of cardiac troponins with fatal CVD, assessment of hs-cTnT in the PROSPER study yielded greater improvements for predicting fatal CVD than overall CVD. For fatal CVD, it yielded improvements in the C-index as well as categorical and continuous NRIs. For the overall CVD outcome, hs-cTnT assessment only improved the continuous NRI.

Another group of biomarkers that has emerged as a potential adjunct to CVD risk prediction are the natriuretic peptides. In the Natriuretic Peptides Studies Collaboration, a large collaborative individual-participant-data meta-analysis, NT-proBNP demonstrated associations with CVD (RR: 1.76; 95% CI: 1.56 to 1.98) and CHD (RR: 1.67; 95% CI: 1.45 to 1.93) that were of similar magnitude to those observed in PROSPER for hs-cTnT (48). The association between hs-cTnT and CVD risk was weakened in PROSPER after adjustment for NT-proBNP but remained significant. It might be that a combination of these biomarkers or a more extensive panel of complementary biomarkers will provide the greatest improvement in prediction. However, this approach might be limited by cost, which requires further study.

Furthermore, the data presented from PROSPER and studies in the current meta-analysis all classified participants on the basis of a single measurement of cardiac troponin. Diurnal variability in cardiac troponin has been observed with moderately higher levels during the morning (49), and short-term variability was present both in those with and without known coronary artery disease (50). This biological variation will need to be explored further to inform selection of appropriate cutoffs for use in clinical practice. Evaluations of the prognostic value of changes in cardiac troponin over time have suggested that the trajectory of cardiac troponin might provide additional prognostic information (12,51).

Recent data from the WOSCOPS (West of Scotland Coronary Prevention Study) trial showed that pravastatin significantly lowered hs-cTnI in a manner consistent with lower CVD risk (28). This recent paper, along with our summation of available prospective data on troponins and CVD risk, suggests that more research on troponins as markers of clinical utility beyond the diagnosis of an acute coronary syndrome is urgently needed.

**STUDY LIMITATIONS.** This study provided de novo data from the PROSPER study and was strengthened by concurrent reporting of a comprehensive review of the literature regarding the association between cardiac troponin and incident CVD. Transformation of study-specific HRs to reflect RR between those with cardiac troponin values in the upper third compared with the lower third allowed a common scale to be used when pooling studies and has been used in the assessment of a number of biomarkers (52). It did, however, assume that the relationship between the biomarker of interest and disease risk was linear. In the meta-analysis, there was significant between-study heterogeneity that could have resulted from several differences between the included studies as discussed earlier. Inherent limitations exist in the use of study-level data in this meta-analysis, and the availability of individual-participant data would allow for further standardization of analytical techniques, covariate adjustment, and subgroup analysis.

## CONCLUSIONS

Elevated cardiac troponin concentration, well within the normal range, was associated with an increased risk of incident CVD outcomes in the general population. This association was strongest for fatal CVD and persisted after adjustment for conventional CVD risk factors. Further research on cardiac troponin as a useful marker of risk prediction seems warranted.

**ADDRESS FOR CORRESPONDENCE:** Dr. Peter Willeit, Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. E-mail: [peter.willeit@i-med.ac.at](mailto:peter.willeit@i-med.ac.at).

## PERSPECTIVES

### COMPETENCY IN MEDICAL KNOWLEDGE:

Meta-analysis of published studies suggests that people with elevated circulating troponin concentrations in absence of clinically manifest myocardial injury are at a relatively high risk of developing cardiovascular events.

**TRANSLATIONAL OUTLOOK:** Future research is needed to clarify the predictive value of cardiac troponin measurements in relation to conventional cardiovascular risk factors.

## REFERENCES

- Apple FS, Collinson PO. IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. *Clin Chem* 2012;58:54–61.
- Jesse RL. On the relative value of an assay versus that of a test: a history of troponin for the diagnosis of myocardial infarction. *J Am Coll Cardiol* 2010;55:2125–8.
- Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. *N Engl J Med* 2009;361:858–67.
- Iribarren C, Chandra M, Rana JS, et al. High-sensitivity cardiac troponin I and incident coronary heart disease among asymptomatic older adults. *Heart* 2016;102:1177–82.
- Thorsteinsdottir I, Aspelund T, Gudmundsson E, et al. High-sensitivity cardiac troponin I is a strong predictor of cardiovascular events and mortality in the AGES-Reykjavik community-based cohort of older individuals. *Clin Chem* 2016;62:623–30.
- Oluleye OW, Folsom AR, Nambi V, Lutsey PL, Ballantyne CM. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. *Ann Epidemiol* 2013;23:66–73.
- Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. *Circulation* 2011;123:1367–76.
- Folsom AR, Nambi V, Bell EJ, et al. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the Atherosclerosis Risk in Communities Study. *Stroke* 2013;44:961–7.
- Nambi V, Virani SS, Couper D, et al. Biomarkers' association with incident cardiovascular events is not modified by presence/severity of sub clinical carotid atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2016;128 Suppl 22:A14810 (abstr).
- Welsh P, Hart C, Papacosta O, et al. Prediction of cardiovascular disease risk by cardiac biomarkers in 2 United Kingdom cohort studies: does utility depend on risk thresholds for treatment? *Hypertension* 2016;67:309–15.
- Blankenberg S, Salomaa V, Makarova N, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. *Eur Heart J* 2016;37:2428–37.
- deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. *JAMA* 2010;304:2494–502.
- Elkind M, Bartz T, Gottdiener J, et al. Serum cardiac biomarkers independently predict risk of stroke in older adults: the Cardiovascular Health Study. *Neurology* 2013;80 Suppl 7: S09.001 (abstr).
- Imano H, Yamagishi K, Okada T, Kitamura A, Iso H. High-sensitivity cardiac troponin t is an independent predictor for coronary artery disease in Japanese population: the Circulatory Risk in Communities Study. *Circulation* 2016;133 Suppl 1: APO20 (abstr).
- de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA* 2010;304:2503–12.
- Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. *Circulation* 2012;126:1596–604.
- Neumann JT, Havulinna AS, Zeller T, et al. Comparison of three troponins as predictors of future cardiovascular events—prospective results from the FINRISK and BiomaCaRE studies. *PLoS One* 2014;9:e90063.
- Omland T, de Lemos JA, Holmen OL, et al. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. *Clin Chem* 2015;61:646–56.
- Lyngbakken MN, Rosjo H, Holmen OL, et al. Gender, high-sensitivity troponin I, and the risk of cardiovascular events (from the Nord-Trøndelag Health Study). *Am J Cardiol* 2016;118:816–21.
- Everett BM, Zeller T, Glynn RJ, Ridker PM, Blankenberg S. High sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention: impact of statin therapy. *Circulation* 2015;131:1851–60.
- Koenig W, Zierer A, Karakas M, et al. Ultra-sensitive troponin I strongly predicts incident coronary heart disease in the general population. Results from the MONICA/KORA Augsburg Case-Cohort study. *Eur Heart J* 2014;35 Suppl 1:204–5 (abstr).
- Apple FS, Steffen LM, Pearce LA, Murakami MM, Luepker RV. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. *Clin Chem* 2012;58:930–5.
- Eggers KM, Johnston N, Lind L, Venge P, Lindahl B. Cardiac troponin I levels in an elderly population from the community—the implications of sex. *Clin Biochem* 2015;48:751–6.
- Eggers KM, Venge P, Lindahl B, Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. *J Am Coll Cardiol* 2013;61:1906–13.
- Scheven L, de Jong PE, Hillege HL, et al. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. *Eur Heart J* 2012;33:2272–81.
- Eggers KM, Al-Shakarchi J, Berglund L, et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. *Am Heart J* 2013;166:541–8.
- Everett BM, Cook NR, Magnone MC, et al. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. *Circulation* 2011;123:2811–8.
- Ford I, Shah ASV, Zhang R, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. *J Am Coll Cardiol* 2016;68:2719–28.
- Zeller T, Tunstall-Pedoe H, Saarela O, et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. *Eur Heart J* 2014;35:271–81.
- Leistner DM, Klotzsche J, Pieper L, et al. Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention. *Clin Chem* 2012;58:200–8.
- Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. *J Am Coll Cardiol* 2014;64:851–60.
- Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647.
- Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002;360:1623–30.
- Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROSPER Study of Pravastatin in the Elderly at Risk. *Am J Cardiol* 1999;84:1192–7.
- Pencina MJ, D'Agostino SR, D'Agostino JR, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med* 2008;27:157–72.
- Pencina MJ, D'Agostino SR, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. *Stat Med* 2011;30:11–21.
- Chêne G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. *Am J Epidemiol* 1996;144:610–21.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
- Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. *Stat Med* 2004;23:1663–82.
- Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
- McCarthy CP, Yousuf O, Alonso A, Selvin E, Calkins H, McEvoy JW. High-sensitivity troponin as a biomarker in heart rhythm disease. *Am J Cardiol* 2017;119:1407–13.
- Wrigley P, Khoury J, Eckertle B, et al. Prevalence of positive troponin and echocardiogram findings and association with mortality in acute ischemic stroke. *Stroke* 2017;48:1226–32.

43. Parwani AS, Boldt LH, Huemer M, et al. Atrial fibrillation-induced cardiac troponin I release. *Int J Cardiol* 2013;168:2734–7.
44. Seliger SL, Hong SN, Christenson RH, et al. High-sensitive cardiac troponin T as an early biochemical signature for clinical and subclinical heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). *Circulation* 2017;135:1494–505.
45. Caselli C, Prontera C, Liga R, et al. Effect of coronary atherosclerosis and myocardial ischemia on plasma levels of high-sensitivity troponin T and NT-proBNP in patients with stable angina. *Arterioscler Thromb Vasc Biol* 2016;36:757–64.
46. Korosoglou G, Lehrke S, Mueller D, et al. Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. *Heart* 2011;97:823–31.
47. Pastormerlo LE, Agazio A, Benelli E, et al. Usefulness of high-sensitive troponin elevation after effort stress to unveil vulnerable myocardium in patients with heart failure. *Am J Cardiol* 2015;116:567–72.
48. Willeit P, Kaptoge S, Welsh P, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. *Lancet Diabetes Endocrinol* 2016;4:840–9.
49. Klinkenberg LJ, van Dijk JW, Tan FE, van Loon LJ, van Diejen-Visser MP, Meex SJ. Circulating cardiac troponin T exhibits a diurnal rhythm. *J Am Coll Cardiol* 2014;63:1788–95.
50. Nordenskjold AM, Ahlstrom H, Eggers KM, et al. Short- and long-term individual variation in cardiac troponin in patients with stable coronary artery disease. *Clin Chem* 2013;59:401–9.
51. McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. *JAMA Cardiol* 2016;1:519–28.
52. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. *JAMA* 1998;279:1477–82.

---

**KEY WORDS** biomarker, cardiovascular disease, coronary heart disease, primary prevention, stroke, systematic review

---

**APPENDIX** For an expanded Methods section, as well as supplemental figures and tables, please see the online version of this article.